Military, Veterans, Teachers, Nurses and First Responders September 18, 2024 Service Appreciation Initiative to increase access to safe and affordable weight loss treatment Hims & Hers Health, Inc
Introduction Retatrutide (development code LY3437943) is an investigational single-molecule agonist reported to engage three incretin- and metabolism-related receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR)
Creative Proteomics provides the tools, expertise, and flexibility you need to transform carnitine and acylcarnitine data into meaningful biological insight
Source: public community post Individual results vary What These Results Have in Common A few patterns across all three: Fat loss concentrated in the abdominal region that's the glucagon receptor at work Muscle definition improved or held, not declined Results visible within 812 weeks faster than standard GLP-1 timelines None of these look like crash-diet results the body composition shift looks sustained Retatrutide does this better than anything else in the GLP-1 category because it hits all three receptors
in vitro genetic intervention produced lipid droplet aggregation in RNF43-mutated human hepatocellular carcinoma tumor organoids, whereas RNF43/ZNRF3-deficient hepatic epithelial organoids displayed not only lipid droplet aggregation but also reduced differentiation capacity